Home Search
dyadic - search results
If you're not happy with the results, please do another search
Dyadic (DYAI) Scores $10M deal with Sorrento Therapeutics (SNRE).
Share Price up 27% ($4.63 up $1.04) as Wall Street Sorts out the Terms of the Deal.
We've had a Long History With Dyadic Dating...
Committed to Win. C-1 and Dyadic’s (DYAI) Drive to Make Vaccines Affordable Worldwide.
Dyadic International, Inc. (NASDAQ: DYAI) – We are a global biotechnology company focused on further improving and leveraging the patented and proprietary C1 expression...
VIDEO: Dyadic (DYAI) CEO Explains What his Industry is Doing to Defeat Coronavirus (FoxNews).
Jan. 27, 2020 - 5:24 - Dyadic International CEO Mark Emalfarb discusses what’s being done to stop the spread of coronavirus and to...
Could Dyadic (DYAI) $5.75 Provide a Solution to Help Mass Produce Vaccines to Battle...
Dyadic (DYAI) has developed a biomanufacturing technology platform, nicknamed C1 which helps to speed the development, lower the manufacturing cost and potentially improve the...
Dyadic (DYAI) Highlights.
"In just over a year and a half we have entered into over 15 proof of concept collaborations for both human and animal health...
Dyadic (DYAI) $7.00 Called a ‘Gamechanger’ – Gets $14 Price Target.
Highly Respected Wall Street Analyst Jason Kolbert Issues $14.00 Price Target On Dyadic.
Analyst Take: "Potential to be Revolutionary. Dyadic’s C1 shows potential in...
Investor Presentation Slides From Dyadic (DYA) $6.40.
Really, How Do We Do It?
Live Short Term Chart
INVESTOR PRESENTATION
LONGER TERM CHART
Client, see published reports for disclosure and disclaimer details.
Dyadic (DYAI) Uplists to NASDAQ!
JUPITER, FL / ACCESSWIRE / April 15, 2019 / Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on further improving and applying...
Must Watch Video: Dyadic’s (DYAI) Matthew Jones.
Click here to watch the video. It's the proverbial, "everything you wanted to know" about Cho cells.
"We achieved encouraging results, knowledge and experience in...
Latest article
Inbcubator Society Pass (SOPA), Expanding into Private AI Software Companies, and Private AI Data...
Society Pass was riding high earlier this year, after announcing they successfully spun off one of its holding companies, into a publicly traded entity,...
GeoVax (GOVX) Reports Both Favorable Safety and “It’s Working” News for its Cancer...
Official Headline is "GeoVax Announces JCO Oncology Advances Publication Highlighting Favorable Safety and Evidence of Disease Stability of Gedeptin(R) in Recurrent Head & Neck...
Biotech Stock Review. All Ideas, 2020-2025.
Top Ideas as Defined by 'Peak Gain' from 2020 to 2025
This is every stock we've covered and added to the Watch List during that...
